The percentage of invasive penicillin-nonsusceptible pneumococci (PNSSP) isolated in Italy in the seven-valent pneumococcal conjugate vaccine (PCV7) era moderately increased in comparison to the pre-PCV7 era. Increase of nonvaccine serotypes was observed among PNSSP. The most frequent PNSSP clones were the same as those identified in the pre-PCV7 era, although they were present in different proportions. Clonal expansion, emergence of new clones, and acquisition of penicillin resistance by established clones contributed to the maintenance of penicillin resistance.
tions of low-level (MIC, 0.12 to 1 g/l) and high-level (MIC, Ͼ1 g/l) PEN resistance were used for epidemiological purposes and for comparison with previous studies. The presence of ERY resistance genes was examined in all PNSSP by PCR (16) . Pulsedfield gel electrophoresis (PFGE), multilocus sequence typing (MLST), and pbp2b/pbp2x restriction analysis were used to define clonal groups, as previously described (6, 7) . At least one isolate from each PFGE type containing Ͻ10 isolates and at least 3 isolates from each PFGE type containing Ն10 isolates were submitted to MLST. The sequence types (STs) obtained were considered related if they were identical, a single-locus variant (SLV), or a double-locus variant (DLV) of each other. In order to identify pneumococcal clones, STs were compared to those of the international clones of the Pneumococcal Molecular Epidemiology Network (PMEN; http://www.sph.emory.edu/PMEN/) and to those available at the MLST website (http://www.mlst.net) by using eBURST to define clonal complexes (CCs). Therefore, each clone was identified by the related PMEN clone, its ST, and the corresponding CC.
Overall, 778 invasive isolates were obtained in the years 2006 to 2010, representing approximately one-third of all the reported IPD cases, with 219 isolates (28.1%) obtained from children under 5 years old. Among these isolates, 218 (28.0%) belonged to VS and 560 (72.0%) to NVS. The most frequent serotypes, in ranked order, were 19A (13.7%), 1 (12.3%), 14 (10.7%), 3 (9.4%), and 7F (9.1%).
A total of 112 isolates (14.4%) were PNSSP (MIC, Ն0.12 g/ l), and of these, 40 (35.7%) were isolated from children under 5 years old. Sixty-three out of 112 PNSSP (56.2%) were VS, and 49 (43.8%) belonged to NVS. The serotypes recovered are shown in Table 1 . High-level resistance to PEN (MIC, Ͼ1 g/ml) was found in 34 isolates and was mostly associated with serotypes 9V, 14 (Table 2) . Clonal diversity within each serotype is shown in Table 2 : among VS, serotypes 19F, 23F, and 6B showed the highest genetic diversity, and among NVS, serotype19A showed the highest genetic diversity. While in the pre-PCV7 era PNSSP of serotype 19A was only found associated with Sweden 15A -25/ST63/CC63 (6), in this study 19A was associated with four clones (Table 2) . Overall, 13 and 15 different restriction profiles were detected for pbp2b and pbp2x genes, respectively, and 28 different compos- ite pbp2b/pbp2x profiles were obtained (Table 2) . pbp2b restriction profiles appeared to be specific for the different clones and conserved over time, strongly supporting the use of pbp2b restriction profiles as typing markers for PNSSP strains. On the contrary, half of the pbp2x restriction profiles were shared between different PNSSP clones, indicating a frequent horizontal exchange of this gene. The presence of the same pbp2x profile in two different clones could also be a marker of a capsular switch phenomenon. As reported by Brueggemann et al. (3), pbp2x can be involved in recombinational events that include the capsular locus between different pneumococcal clones. When the results were compared with those obtained in the pre-PCV7 era (2001 to 2003), differences in the relative frequencies of PNSSP, VS, NVS, and clones were observed. PNSSP represented approximately 14% of the invasive pneumococci in the PCV7 era, a percentage slightly higher than that found in the period antecedent to PCV7 implementation, which was 10% to 12% (7). Among PNSSP, VS decreased from 78.9% to 56.2%, with a concurrent increase in NVS from 21.1% to 43.8%. The proportion of VS among PNSSP from 2006 to 2010 was 2-fold higher than that among the nonselected invasive strains from the same period, indicating that most of the antibiotic resistance was still associated with VS.
Within NVS, an increment in the proportion of 19A, 24F, 15A, and 6A was noted, while 35F, which was well represented in the prevaccine era among PNSSP (7), was not detected.
Seven clones, accounting for 76.8% of the PNSSP isolated in the PCV7 era, were recovered in both periods, although in different proportions (Fig. 1) . Clonal expansion appears to represent the primary mechanism for serotype replacement and for the maintenance of antimicrobial resistance. Two clones, Sweden 15A -25/ST63/CC63, expressing multiple VS and NVS serotypes, and Denmark 14 -32/ST230/CC230, expressing NVS 19A and 24F, expanded in the PCV7 era, ranking second and third, respectively. The increase of these two clones, associated with both carriage and disease, has been reported in several countries (1, 8, 17, 22) . Denmark 14 -32/ST230/CC230 was detected in Italy as far back as 1997, in association with serotype 24F isolates (19) .
We observed that some VS clones, present in Italy before the introduction of PCV7, appeared to be more refractory to extinction than others; for instance, Spain 9V -3/ST156, which ranked first in both periods, showed a limited decrease, in comparison with Spain 23F -1/ST81 and Spain 6B -2/ST90. The presence of the same antibiotic-resistant clones in the periods before and after PCV7 implementation, and also of an evolution in their proportions leading to persistence of antimicrobial resistance, has already been documented in a colonization study from Portugal (22) .
Other mechanisms that seem to have significantly contributed to the evolution of PNSSP in Italy are introduction of new clones and acquisition of penicillin resistance by established clones. For example, Taiwan 19F -14/ST236/CC320 and Colombia 23F -26/ ST338/CC156 clones were not detected in the prevaccine era (10) and emerged in Italy only in 2008 and 2007, respectively. These two clones have different characteristics: Taiwan 19F -14/ST236/ CC320 comprises isolates with high-level penicillin resistance, intermediate or full resistance to ceftriaxone (MIC range, 1 to 2 g/ml), and resistance to erythromycin (MIC, Ͼ256 g/ml), while Colombia 23F -26/ST338/CC156 comprises isolates with lowlevel penicillin resistance that are fully susceptible to the other antibiotics. Both these clones have expanded successfully in different areas of the globe. Taiwan 19F -14/ST236/CC320 spread rapidly in Asian countries before PCV7 introduction (4, 21) ; in the United States it has been associated with the emergence of MDR serotype 19A isolates after PCV7 implementation (2) . Colombia 23F -26/ST338/CC156 has been increasingly found in the United States and Japan (13, 17) . De novo acquisition of penicillin resistance has been detected in 2 PNSSP clones, new clone/ST473/ CC473 and England 14 -9/ST9/CC15, both found in the pre-PCV7 era only in association with penicillin-susceptible isolates (6) .
It has been suggested that PCV7 acts as a "serotype filter," because its effect on the prevalence of a particular strain is predictable on the basis of the serotype of the strain, with little effect on the genetic background (15) . Our findings about the high clonal diversity of serotype 19A PNSSP, the emergence of new PNSSP clones, and the disappearance of others seem to indicate that the vaccine exerts a significant effect also on the genetic background of pneumococci.
Although PCV7 had an important impact in preventing IPD, a second-generation vaccine containing 6 additional serotypes (PCV13) has been developed. PCV13 was introduced in Italy at the end of 2010, and according to our study it should cover 78.5% of infections due to PNSSP. Serotypes 15A and 24F represent the most abundant PNSSP serotypes not covered by the new vaccine. Continuous surveillance of the pneumococcal population following the introduction of PCV13 is essential to evaluate the impact of the new vaccine on the evolution of the pneumococcal population.
